Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

Clinical trial NCT06997276 · RECRUITING

Trial details

NCT number: NCT06997276
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Healthy Hepatic Impairment

Start date: 2025-05-07
Primary completion: 2026-09-30
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.